348 related articles for article (PubMed ID: 34508829)
41. The hypoxia conditioned mesenchymal stem cells promote hepatocellular carcinoma progression through YAP mediated lipogenesis reprogramming.
Liu Y; Ren H; Zhou Y; Shang L; Zhang Y; Yang F; Shi X
J Exp Clin Cancer Res; 2019 May; 38(1):228. PubMed ID: 31142342
[TBL] [Abstract][Full Text] [Related]
42. Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells.
Zhou TY; Zhuang LH; Hu Y; Zhou YL; Lin WK; Wang DD; Wan ZQ; Chang LL; Chen Y; Ying MD; Chen ZB; Ye S; Lou JS; He QJ; Zhu H; Yang B
Sci Rep; 2016 Aug; 6():30483. PubMed ID: 27476430
[TBL] [Abstract][Full Text] [Related]
43. Overexpression of Rac GTPase Activating Protein 1 Contributes to Proliferation of Cancer Cells by Reducing Hippo Signaling to Promote Cytokinesis.
Yang XM; Cao XY; He P; Li J; Feng MX; Zhang YL; Zhang XL; Wang YH; Yang Q; Zhu L; Nie HZ; Jiang SH; Tian GA; Zhang XX; Liu Q; Ji J; Zhu X; Xia Q; Zhang ZG
Gastroenterology; 2018 Oct; 155(4):1233-1249.e22. PubMed ID: 30009820
[TBL] [Abstract][Full Text] [Related]
44. PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells.
Sponziello M; Verrienti A; Rosignolo F; De Rose RF; Pecce V; Maggisano V; Durante C; Bulotta S; Damante G; Giacomelli L; Di Gioia CR; Filetti S; Russo D; Celano M
Endocrine; 2015 Nov; 50(2):434-41. PubMed ID: 25837309
[TBL] [Abstract][Full Text] [Related]
45. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM
Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878
[TBL] [Abstract][Full Text] [Related]
46. Protective and therapeutic effects of sildenafil and tadalafil on aflatoxin B1-induced hepatocellular carcinoma.
Chhonker SK; Rawat D; Koiri RK
Mol Cell Biochem; 2021 Feb; 476(2):1195-1209. PubMed ID: 33216253
[TBL] [Abstract][Full Text] [Related]
47. FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling.
Yang Y; Zhang Y; Cao J; Su Z; Li F; Zhang P; Zhang B; Liu R; Zhang L; Xie J; Li J; Zhang J; Chen X; Hong A
J Exp Clin Cancer Res; 2023 Apr; 42(1):96. PubMed ID: 37085881
[TBL] [Abstract][Full Text] [Related]
48. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
[TBL] [Abstract][Full Text] [Related]
49. YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis.
Gao R; Kalathur RKR; Coto-Llerena M; Ercan C; Buechel D; Shuang S; Piscuoglio S; Dill MT; Camargo FD; Christofori G; Tang F
EMBO Mol Med; 2021 Dec; 13(12):e14351. PubMed ID: 34664408
[TBL] [Abstract][Full Text] [Related]
50. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
Wu J; Chai H; Li F; Ren Q; Gu Y
Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
[TBL] [Abstract][Full Text] [Related]
51. The Hippo Pathway Effector YAP Promotes Ferroptosis via the E3 Ligase SKP2.
Yang WH; Lin CC; Wu J; Chao PY; Chen K; Chen PH; Chi JT
Mol Cancer Res; 2021 Jun; 19(6):1005-1014. PubMed ID: 33707306
[TBL] [Abstract][Full Text] [Related]
52. TAZ-regulated expression of IL-8 is involved in chemoresistance of hepatocellular carcinoma cells.
Zhang H; Yu QL; Meng L; Huang H; Liu H; Zhang N; Liu N; Yang J; Zhang YZ; Huang Q
Arch Biochem Biophys; 2020 Oct; 693():108571. PubMed ID: 32898567
[TBL] [Abstract][Full Text] [Related]
53. SDHA/B reduction promotes hepatocellular carcinoma by facilitating the deNEDDylation of cullin1 and stabilizing YAP/TAZ.
Yuan T; Zhou T; Qian M; Du J; Liu Y; Wang J; Li Y; Fan G; Yan F; Dai X; Li X; Wu Y; Dong X; He Q; Zhu H; Yang B
Hepatology; 2023 Jul; 78(1):103-119. PubMed ID: 35713976
[TBL] [Abstract][Full Text] [Related]
54. PDE4D binds and interacts with YAP to cooperatively promote HCC progression.
Ren H; Chen Y; Ao Z; Cheng Q; Yang X; Tao H; Zhao L; Shen A; Li P; Fu Q
Cancer Lett; 2022 Aug; 541():215749. PubMed ID: 35597479
[TBL] [Abstract][Full Text] [Related]
55. BET proteins inhibitor JQ-1 impaired the extinction of remote auditory fear memory: An effect mediated by insulin like growth factor 2.
Duan Q; Huang FL; Li SJ; Chen KZ; Gong L; Qi J; Yang ZH; Yang TL; Li F; Li CQ
Neuropharmacology; 2020 Oct; 177():108255. PubMed ID: 32730819
[TBL] [Abstract][Full Text] [Related]
56. The calcimimetic agent cinacalcet inhibits hepatocellular carcinoma via YAP/TAZ suppression.
Zheng L; Du J; Ge F; Qian M; Yang B; He Q; Weng Q; Zhu H
Pharmazie; 2021 Oct; 76(10):511-514. PubMed ID: 34620281
[TBL] [Abstract][Full Text] [Related]
57. Reactive oxygen species-induced activation of Yes-associated protein-1 through the c-Myc pathway is a therapeutic target in hepatocellular carcinoma.
Cho Y; Park MJ; Kim K; Kim SW; Kim W; Oh S; Lee JH
World J Gastroenterol; 2020 Nov; 26(42):6599-6613. PubMed ID: 33268949
[TBL] [Abstract][Full Text] [Related]
58. The YAP-TEAD4 complex promotes tumor lymphangiogenesis by transcriptionally upregulating CCBE1 in colorectal cancer.
Song J; Dang X; Shen X; Liu Y; Gu J; Peng X; Huang Z; Hong W; Cui L; Liu CY
J Biol Chem; 2023 Apr; 299(4):103012. PubMed ID: 36781122
[TBL] [Abstract][Full Text] [Related]
59. Yes-associated protein (YAP) induces a secretome phenotype and transcriptionally regulates plasminogen activator Inhibitor-1 (PAI-1) expression in hepatocarcinogenesis.
Marquard S; Thomann S; Weiler SME; Bissinger M; Lutz T; Sticht C; Tóth M; de la Torre C; Gretz N; Straub BK; Marquardt J; Schirmacher P; Breuhahn K
Cell Commun Signal; 2020 Oct; 18(1):166. PubMed ID: 33097058
[TBL] [Abstract][Full Text] [Related]
60. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
